Product Description: Thioacetamide (TAA) is an indirect hepatotoxin and causes parenchymal cell necrosis. Thioacetamide requires metabolic activation by microsomal CYP2E1 to thioacetamide-S-oxide initially and then to thioacetamide-S-dioxide, which is a highly reactive metabolite, and its reactive metabolites covalently bind to proteins and lipids thereby causing oxidative stress and centrilobular necrosis. Thioacetamide can induce chronic liver fibrosis, encephalopathy and other events model[1][2][3][4].
Applications: COVID-19-immunoregulation
Formula: C2H5NS
References: [1]Wallace MC, et, al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim. 2015 Apr;49(1 Suppl):21-9./[2]Chen IS, et, al. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric. 2012 May;92(7):1441-7./[3]Miranda AS, et, al. A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice: a behavioral and neurochemical study. Arq Neuropsiquiatr. 2010 Aug;68(4):597-602./[4]Yeom HJ, et, al. Expression analysis of early response-related genes in rat liver epithelial cells exposed to thioacetamide in vitro. J Vet Med Sci. 2009 Jun;71(6):719-27.
CAS Number: 62-55-5
Molecular Weight: 75.13
Compound Purity: 98.0
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 50 mg/mL (ultrasonic)
Target: Necroptosis
English
Deutsch
